Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05937841 · ClinicalTrials.gov registry record · Early Phase 1

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

A Early Phase 1 study of Preeclampsia Postpartum, sponsored by Anna Stanhewicz, PhD.

Recruiting
Registry status
Early Phase 1
Development phase
30
Enrollment target
1
Study location

NCT05937841: Recruiting Early Phase 1 study of Preeclampsia Postpartum, sponsored by Anna Stanhewicz, PhD.

NCT05937841 is a Early Phase 1 study of Preeclampsia Postpartum that is actively recruiting participants, run by Anna Stanhewicz, PhD. The registered enrollment target is 30 participants, below the 70-participant average among 8 other Preeclampsia Postpartum trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05937841, a Early Phase 1 study of Preeclampsia Postpartum, is actively recruiting participants, sponsored by Anna Stanhewicz, PhD.

RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. The purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. This will help increase understanding of the mechanisms of angiotensin II receptors in these women, and how activation of these receptors may restore microvascular function. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.

Primary Outcome

Cutaneous vascular vasodilator response (cutaneous conductance; %max) to exogenous compound 21 perfusion; intradermal microdialysis for the local delivery of compound 21

Conditions Studied

Interventions

  • DRUG Compound 21

Study Locations (1)

Iowa

  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-06-28
Est. Completion 2026-06-01
Phase Early Phase 1
Anna Stanhewicz, PhD

14 total trials

What NCT05937841 shows while recruiting

NCT05937841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 70-participant average among 8 other Preeclampsia Postpartum trials with a reported enrollment target (57% lower).

The record links to 1 condition, with Preeclampsia Postpartum appearing as the primary indexed condition, and to 1 intervention - of which Compound 21 is the first listed.

NCT05937841 reports a single indexed study location in Iowa.

Frequently Asked Questions

What is clinical trial NCT05937841 about?

NCT05937841 is a clinical study titled "Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia". Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that o...

What is the current status of trial NCT05937841?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-06-28. Estimated completion is 2026-06-01.

What conditions does trial NCT05937841 study?

This clinical trial studies the following conditions: Preeclampsia Postpartum.

What interventions are being tested in trial NCT05937841?

The interventions under investigation include: Compound 21 (DRUG).

Who is sponsoring clinical trial NCT05937841?

This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05937841 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Preeclampsia Postpartum

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05937841's enrollment target sits among peer trials

30 8th of 8 higher than 1 of 8 other Preeclampsia Postpartum trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Preeclampsia Postpartum trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05937841, the US trial registry maintained by the National Library of Medicine. NCT05937841 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.